Cash, cash equivalents, and marketable securities were $87.1 million as of March 31, 2025, compared to $97.8 million as of December 31, 2024. The Company expects its cash, cash equivalents and marketable securities will fund its operational plans into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil presents data on oral small molecule program including VG-3927
- Vigil Neuroscience Reports 2024 Results and Clinical Progress
- Vigil Neuroscience files to sell 5.38M shares of common stock for holders
- Vigil Neuroscience Inc.: Promising Biomarker Data and Strategic Advancements Justify Buy Rating
- Vigil Neuroscience price target lowered to $14 from $17 at H.C. Wainwright